GLP-1 drugs fueled a jump in R.I. health care spending, nearly tripling in three years, report finds

Boston Globe

13-05-2025

Advertisement
The latest iteration arrives as Americans have, at rapid pace, turned to GLP-1s to lose weight in recent years.
Get Rhode Island News Alerts
Sign up to get breaking news and interesting stories from Rhode Island in your inbox each weekday.
Enter Email
Sign Up
Related
:
Data from the health analytics firm, Real Chemistry, showed between 2023 and 2024,
'It is no surprise that GLP-1s have the potential to appeal to many Rhode Island residents, as nearly one in three residents was obese in 2023,' states the Office of the Health Insurance Commissioner's
While the medications have provided benefits to counteract obesity and related health complications, the drugs come at a premium:
Advertisement
'Due to high prices and increasing utilization, GLP-1 drugs have quickly become a leading source of retail pharmacy spending,' the report states. 'Because they are a long-term maintenance medication, and their use is expanding, they will be a major source of spending growth for years to come – even before accounting for price increases.'
According to the report, retail pharmacy spending in the state would have grown by only 3.8 percent
if not for GLP-1 medications, instead of 7.9 percent. The analysis, which relies on
Related
:
Collectively, across the three years, the state spent $121.4 million on those drugs alone.
'A small number of GLP-1 medications made up a significant amount of spending, underscoring their extremely high price points,' the report states.
'The impact of these medications on retail pharmacy spending is even more pronounced considering that patients typically use them for the long-term,' the report states. 'The annual cost of Trulicity, for example, is over $10,000, according to these data.'
The report concluded GLP-1s are 'not cost-effective at their current prices, and are largely unavailable to people with lower incomes.'
'It is important for Rhode Islanders to get the care and medications they need to live the healthiest lives possible, but at prices that are not burdensome and a deterrent to access,' the report states.
Overall, the report found hospital and drug costs were the primary expenses that bumped up health care spending in the Ocean State, which rose across all major insurance markets. Spending per person hit $6,735 in the commercial market, a 6.9 percent increase from 2022; $14,000 in Medicare, a 8.7 percent increase; and $7,678 in Medicaid, up 6.7 percent.
Advertisement
Other findings from the report include a sharp increase in per-person hospital spending, as outpatient hospital costs in the commercial market jumped 11.3 percent to $1,801 per person from $1,618, an increase 'driven by increasing prices and utilization.' The report also found 'hospital settings continue to drive higher costs for the same services' provided in non-hospital settings.
'This year's report shows that we must keep pushing for smarter solutions,' Governor Dan McKee said in a statement. 'That's why my administration has taken action to strengthen primary care and reduce unnecessary costs — and why my FY 2026 budget continues to prioritize investments that improve access, affordability, and quality.'
Christopher Gavin can be reached at